Completed PHASE1 INTERVENTIONAL NCT00005816

Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer

Active Immunotherapy of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA

Sponsor: Duke University

Conditions Kidney Cancer

Interventions conventional surgery therapeutic autologous dendritic cells

Updated 6 times since 2017 Last updated: Mar 19, 2013 Started: Feb 29, 2000 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005816, this PHASE1 trial focuses on Kidney Cancer and remains completed. Sponsored by Duke University, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke University
National Cancer Institute (NCI)

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States